TAC-001: A Toll-like 9 Receptor Agonist Antibody Conjugate for Solid Tumors
Time: 2:15 pm
day: Conference Day 1
Details:
- Understanding the scientific rationale behind TAC-001, a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22
- Outlining the ongoing TAC-001 phase ½ clinical trial for advanced or metastatic solid tumors
- Exploring the potential of Tallac’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform for systemically administered immune agonist conjugates
